OTCMKTS:ESALY - Eisai Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$108.27
▲ +4.65 (4.49%)
1 month | 3 months | 12 months
Get New Eisai Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ESALY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ESALY

Average Price Target: $0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Eisai in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $108.27.

Buy

The current consensus among 2 contributing investment analysts is to buy stock in Eisai. This rating has held steady since August 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 3 sell ratings
12/27/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
3/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
6/24/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/22/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/21/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/20/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/17/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
11/5/2020Jefferies Financial GroupUpgradeHold ➝ Buy
9/8/2020Jefferies Financial GroupDowngradeBuy ➝ Hold
9/24/2019Jefferies Financial GroupInitiated CoverageBuy
9/17/2019Daiwa Capital MarketsDowngradeNeutral ➝ Sell
8/5/2019CitigroupUpgradeSell ➝ Neutral
3/25/2019UBS GroupReiterated RatingNeutral ➝ Sell
3/22/2019Nomura SecuritiesReiterated RatingBuy ➝ Reduce
3/22/2019CitigroupDowngradeNeutral ➝ Sell
7/7/2016UBS GroupInitiated CoverageBuy
(Data available from 6/20/2016 forward)
Eisai logo
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. Eisai Co., Ltd. has a research collaboration agreement with Wren Therapeutics Ltd. for the discovery of small molecules that target synuclein for the potential treatment of synucleinopathies, including Parkinson's disease and dementia with Lewy bodies; and a collaboration with BioLabs for the launch of the Eisai Innovation Center BioLabs, a shared lab and office space for start-ups to innovate in the field of neurological diseases. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.
Read More

Today's Range

Now: $108.27
Low: $108.14
High: $109.27

50 Day Range

MA: $73.52
Low: $62.84
High: $116.03

52 Week Range

Now: $108.27
Low: $61.95
High: $129.79

Volume

20,918 shs

Average Volume

28,152 shs

Market Capitalization

$32.11 billion

P/E Ratio

77.89

Dividend Yield

0.60%

Beta

0.32

Frequently Asked Questions

What sell-side analysts currently cover shares of Eisai?

The following equities research analysts have issued stock ratings on Eisai in the last year: Jefferies Financial Group Inc., JPMorgan Chase & Co., and Zacks Investment Research.
View the latest analyst ratings for ESALY.

What is the current price target for Eisai?

0 Wall Street analysts have set twelve-month price targets for Eisai in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Eisai in the next year.
View the latest price targets for ESALY.

What is the current consensus analyst rating for Eisai?

Eisai currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ESALY will outperform the market and that investors should add to their positions of Eisai.
View the latest ratings for ESALY.

What other companies compete with Eisai?

How do I contact Eisai's investor relations team?

Eisai's physical mailing address is 4-6-10 Koishikawa Bunkyo-ku, Tokyo M0, 112-8088. The company's listed phone number is 813-3817-3700. The official website for Eisai is www.eisai.co.jp.